
Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

An expert reviews cabotegravir, islatravir, lenacapavir, and what other promising agents that could redefine long-term HIV prevention.

A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).

This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.

The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.

An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.

With the unpredictability of when it will appear, and its propensity to be multidrug-resistant, this particular pathogen is challenging to diagnose and treat.

New York City-based Montefiore Health System has adapted its inpatient treatment over the course of the last year to help enable better patient care and reduce healthcare-acquired infections (HAI).

The STOP Spillover project is aiming to prevent remerging infectious disease outbreaks.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

Montefiore Health System has a long history of treating infectious disease, and with the current pandemic and other emerging pathogens, they remain vigilant to potential outbreaks.

August is National Immunization Month. With the FDA’s approval of the Pfizer-BioNTech COVID-19 vaccine, providers will likely be having more conversations with patients on the topic. Motivational interviewing is an emerging strategy for providers to consider in their conversations with patients who are reluctant to get the vaccine.

What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

Infection preventionists at UCLA used active surveillance screening and technology to take a proactive approach to staving off any potential outbreaks of the emerging fungal infection in their health system.

Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.

Considering the care team members who need to help infectious disease specialists and pharmacists carry the stewardship torch.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

A conversation with Anna Legreid Dopp, Pharm. D.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

What risks and benefits need to be considered with the return of in-person classes?